ReleaseWire Connect

Cancer is one of the leading causes of death worldwide. According to the World Health Organization, about 8.2 million deaths occurred in 2012 due to cancer. The most common kinds of cancer which tend to result in death are lung cancer, liver cancer, stomach cancer, colorectal cancer, breast cancer and oesophageal cancer. Apart from the mature chemotherapy market, biotherapy has emerged as a new approach for cancer treatment. Biotherapy boosts the body's immune system to slow or stop the growth of cancer cells. Growing demand for personalized medicine and the introduction of novel approaches are expected to drive the market growth. Astra Zeneca PLC, Biogen IDEC, Bristol-Myers Squibb, Sanofi, Merck, Johnson & Johnson, Schering-Plough and Roche are some players in Cancer Therapeutics and Biotherapeutic Market.

Uterine fibroid embolization (UFE) is an effective, non-surgical method used to treat uterine fibroids in the fertile women population. It is performed with the help of uterine fibroid embolization agents, delivered to the tumor by micro-catheters. Uterine fibroids are benign growths in the uterus that can be asymptomatic and seen during the fertile period. Depending on the size and location of the fibroid in uterus, it can cause pain and heavy bleeding during menstrual cycle and affect the ability of a woman to conceive. The embolization agents block the arteries supplying blood to the tumor and force them to shrink. It is the most common form of tumor found in female reproductive system and therefore it is now one of the rising concerns amongst women. The increased awareness about the uterine fibroids amongst women and popularity of minimally invasive procedure will drive the global uterine fibroid embolization market agents. In addition, the fact that UFE allows woman to preserve their uterus, otherwise not possible with full or even partial hysterectomy will further drive the market. Even though UFE is emerging as one of the most effective treatment available for UFE, side-effects such as infections, premature menopause, inflammation, and loss of menstrual periods can act as a barrier in the growth of the uterine fibroid embolization agents market.

Increasing count of individuals suffering with cancer and cardiac ailments foster the demand of radiopharmaceuticals market. Factors expected to boost the growth of Asia Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes market are rising awareness of radiopharmaceuticals coupled with increasing use of spect & pet scans results are the. However, very short half-life of radiopharmaceuticals along with cost of capital of scanners are the factors that are expected to hamper the growth of the market. The market faces stiff competition from conventional diagnostic procedures which is a key market challenge. Potential generation of radioisotopes in the pipeline along with cancer treatment based on alpha radioimmunotherapy and Cyclotron-Based Production are the factors that is expected to create abundant growth opportunities in this market. Japanese reactors unable to suffice the domestic nuclear demand is a key threat faced by market players. Investments on discovery new radioisotopes and the use of radiopharmaceuticals and stable isotopes novel applications such as neurological applications are the winning imperatives adopted by market players to gain a stronghold of the market.

The Human Microbiome refers to the group of microorganisms that reside on skin layers, and in saliva, conjunctiva, oral mucosa and the gastrointestinal tract (GIT). It includes bacteria, archaea and fungi. Despite being parasites, these microorganisms perform tasks which are beneficial for the human host in maintaining health. The human microbiome has fascinated researchers in the past few years due to the usefulness of these microorganisms in terms of health maintenance and treatment of certain diseases. The Human Microbiome Project, which was conducted in 2012, reported that more than 10,000 microbial species live in the human ecosystem and comprise trillions of cells, making up 1%-3% of the total body mass. Conversely, microorganisms that are omnipresent in humans can sometimes turn virulent and cause sickness or even death. Researchers are focusing on improving the efficiency of medical treatments by developing a therapeutics course comprising of a subset of microorganisms. These research studies are currently under clinical development and are expected to fuel the market growth in the near future. Advancement in microbiome technologies would assist in determining the probable solutions for serious diseases; these technologies would thus improve healthcare outcomes. MicroBiome Therapeutics LLC, Enterome Bioscience, Pfizer and Johnson & Johnson are some of the key players in Microbiome Therapeutics Market. Enterome has developed a diagnostic tool for the detection of inflammatory bowel disease by using a genetic sequencing platform.

Hemoglobinopathy is a genetic disorder that causes structural abnormalities in hemoglobin molecules, particularly defective globin chains. Hemoglobinopathies are inherited single-gene disorders of which sickle cell disease is the most common kind. There is a high prevalence of Hemoglobinopathies in Africa, Southeast Asia and the Mediterranean basin. If left untreated, critical cases of hemoglobinopathies lead to anemia, organ dysfunction or death. Gel electrophoresis and complete blood count are used as diagnostic tests to determine the presence of hemoglobinopathies. The disease does not have a permanent cure; this has resulted in a growing demand for new product innovations in the pharmaceutical sector. Additionally, the high prevalence of the disease and the national control program are driving the need for drug therapy in developing economies. Alnylam Pharmaceuticals, Gamilda Cell, Sangamo Biosciences, Cancer Therapeutics CRC Pty Ltd and Biogen Idec are some of the key players in hemoglobinopathies market. These companies have invested huge sums of money in research and development of hemoglobinopathies to develop a permanent cure for this disease. NiCord, ZFP and ALN-TMP are some of the current products available in the market. Companies have adopted the strategy of collaboration and licensing to supplement their research activities.

Audiology devices are electronic devices used by audiologists for the diagnosis and treatment of hearing impairment or hearing loss. They are also used for monitoring or studying hearing. Hearing impairment or frequent hearing loss is often associated with old age and is a growing problem globally. The high prevalence of hearing problems is precipitated by the growing ageing population and the rising incidence of impairment and loss of hearing among younger generations; these factors are therefore the key drivers for Audiology Devices Market. Moreover, the cosmetic appeal of hearing devices and high prevalence of deafness is spurring the growth of this market. Additionally, technological advancement, cost-effective and efficient devices (such as wireless devices), and widespread acceptance of novel devices amongst the geriatric population is also expected to fuel market growth.

The hospital assets management system market helps to manage and protect hospital equipment. It uses automated software systems to monitor the environment in hospital campus.

Intraoperative imaging (IOI) system is used to have a better view of sections of body during surgery. It is widely used by surgeons in neurosurgery applications for removing brain tumor and interventional neurovascular procedures. The examination of brain is carried out using IOI system while performing aneurysm surgery, repairing congenital abnormalities, and removing traumatic blood clots. It also provides precision when performing complex operations in orthopedics and spinal surgeries. The key benefits of IOI system include increase in safety while performing surgeries and reduction in possibilities of having multiple surgeries.

Popularity of simulation technologies and rising demand for less invasive treatment are driving the world mannequin based simulation market. However, lack of sufficient funds have hindered the growth of the market to a greater extent. Moreover, increasing focus on patients safety is anticipated to create greater opportunities.

The anti-snoring devices and snoring surgery market has gained traction in the recent years due to growing consciousness about the ill effects of snoring and sleep apnea, and these treatments have become the central point of attention for clinical reasons.